Notice: This company has been marked as potentially delisted and may not be actively trading. ContraVir Pharmaceuticals (CTRV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CTRV vs. REVB, ERNA, GRTX, GLMD, PBM, PBLA, CYTO, VRPX, ONCT, and TRVNShould you be buying ContraVir Pharmaceuticals stock or one of its competitors? The main competitors of ContraVir Pharmaceuticals include Revelation Biosciences (REVB), Eterna Therapeutics (ERNA), Galera Therapeutics (GRTX), Galmed Pharmaceuticals (GLMD), Psyence Biomedical (PBM), Panbela Therapeutics (PBLA), Altamira Therapeutics (CYTO), Virpax Pharmaceuticals (VRPX), Oncternal Therapeutics (ONCT), and Trevena (TRVN). These companies are all part of the "medical" sector. ContraVir Pharmaceuticals vs. Revelation Biosciences Eterna Therapeutics Galera Therapeutics Galmed Pharmaceuticals Psyence Biomedical Panbela Therapeutics Altamira Therapeutics Virpax Pharmaceuticals Oncternal Therapeutics Trevena Revelation Biosciences (NASDAQ:REVB) and ContraVir Pharmaceuticals (NASDAQ:CTRV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership. Is REVB or CTRV more profitable? Revelation Biosciences' return on equity of -193.51% beat ContraVir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Revelation BiosciencesN/A -193.51% -84.00% ContraVir Pharmaceuticals N/A -4,810.77%-130.14% Does the media prefer REVB or CTRV? In the previous week, Revelation Biosciences' average media sentiment score of 0.00 equaled ContraVir Pharmaceuticals'average media sentiment score. Company Overall Sentiment Revelation Biosciences Neutral ContraVir Pharmaceuticals Neutral Which has more volatility & risk, REVB or CTRV? Revelation Biosciences has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Comparatively, ContraVir Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Does the MarketBeat Community prefer REVB or CTRV? ContraVir Pharmaceuticals received 189 more outperform votes than Revelation Biosciences when rated by MarketBeat users. Likewise, 74.49% of users gave ContraVir Pharmaceuticals an outperform vote while only 63.83% of users gave Revelation Biosciences an outperform vote. CompanyUnderperformOutperformRevelation BiosciencesOutperform Votes3063.83% Underperform Votes1736.17% ContraVir PharmaceuticalsOutperform Votes21974.49% Underperform Votes7525.51% Do institutionals and insiders hold more shares of REVB or CTRV? 12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 1.1% of ContraVir Pharmaceuticals shares are owned by institutional investors. 0.2% of Revelation Biosciences shares are owned by insiders. Comparatively, 1.6% of ContraVir Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, REVB or CTRV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevelation BiosciencesN/AN/A-$120K-$16.76-0.02ContraVir PharmaceuticalsN/AN/A-$9.45MN/AN/A SummaryRevelation Biosciences and ContraVir Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks. Ad Stansberry Research2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisisDan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. Get ContraVir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTRV vs. The Competition Export to ExcelMetricContraVir PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$392,000.00$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.1317.19Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.615.094.784.78Net Income-$9.45M$151.83M$120.31M$225.60M ContraVir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTRVContraVir PharmaceuticalsN/A$0.49-7.4%N/A-83.3%$392,000.00N/A0.0014Gap DownREVBRevelation Biosciences0.731 of 5 stars$0.45+3.1%N/A-98.3%$1.95MN/A-0.0310ERNAEterna TherapeuticsN/A$0.36-11.2%N/A-85.4%$1.92M$70,000.000.0010Gap DownHigh Trading VolumeGRTXGalera TherapeuticsN/A$0.03-2.6%N/A-76.3%$1.86MN/A0.0030Gap DownGLMDGalmed Pharmaceuticals0.4246 of 5 stars$2.85+1.8%N/A-31.3%$1.82MN/A0.0020Gap UpPBMPsyence BiomedicalN/A$2.02-14.8%N/AN/A$1.70MN/A0.00N/ANews CoveragePositive NewsGap UpHigh Trading VolumePBLAPanbela TherapeuticsN/A$0.34+7.0%$500.00+145,885.4%-98.1%$1.66MN/A0.007Gap DownCYTOAltamira Therapeutics1.9288 of 5 stars$0.47-9.3%N/A-90.9%$1.60M$320,000.000.0020News CoverageVRPXVirpax Pharmaceuticals1.0654 of 5 stars$0.32-3.2%$3.00+831.7%-90.8%$1.58MN/A0.007ONCTOncternal Therapeutics2.4303 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790,000.00-0.0530Analyst ForecastTRVNTrevena0.9354 of 5 stars$1.60-1.9%$5.00+212.5%-89.8%$1.38M$3.12M0.0040Analyst Forecast Related Companies and Tools Related Companies Revelation Biosciences Competitors Eterna Therapeutics Competitors Galera Therapeutics Competitors Galmed Pharmaceuticals Competitors Psyence Biomedical Competitors Panbela Therapeutics Competitors Altamira Therapeutics Competitors Virpax Pharmaceuticals Competitors Oncternal Therapeutics Competitors Trevena Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTRV) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraVir Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraVir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTRV Stock Alerts